Home » Stocks » BCLI

Brainstorm Cell Therapeutics Inc. (BCLI)

Stock Price: $4.24 USD 0.03 (0.71%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
Pre-market: $4.27 +0.03 (0.71%) Feb 25, 4:51 AM
Market Cap 154.30M
Revenue (ttm) n/a
Net Income (ttm) -31.81M
Shares Out 29.85M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $4.24
Previous Close $4.21
Change ($) 0.03
Change (%) 0.71%
Day's Open 4.28
Day's Range 4.23 - 4.51
Day's Volume 956,882
52-Week Range 3.80 - 17.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 15 hours ago

NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm...

Benzinga - 2 days ago

The FDA's initial review concluded that current data from BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn Phase 3 trial in amyotrophic lateral sclerosis (ALS) does not sufficiently pr...

PRNewsWire - 2 days ago

NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that ...

Benzinga - 2 weeks ago

Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmace...

Other stocks mentioned: INFI, ORTX, VIVO
The Motley Fool - 2 weeks ago

The company isn't giving up on a promising pipeline drug.

PRNewsWire - 2 weeks ago

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial res...

PRNewsWire - 1 month ago

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the p...

PRNewsWire - 1 month ago

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the followin...

PRNewsWire - 2 months ago

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that ...

Insider Monkey - 2 months ago

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our i...

PRNewsWire - 3 months ago

NEW YORK, Nov. 23, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that ...

InvestorPlace - 3 months ago

Brainstorm Cell Therapeutics (BCLI) news for Tuesday has BCLI stock taking a beating following results from its ALS study. The post Brainstorm Cell Therapeutics News: 8 Things for BCLI Stock I...

The Motley Fool - 3 months ago

The company reported disappointing results from a pivotal clinical trial.

PRNewsWire - 3 months ago

NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topli...

PRNewsWire - 3 months ago

PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a lea...

Seeking Alpha - 4 months ago

Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 4 months ago

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial re...

PRNewsWire - 4 months ago

NEW YORK, Oct. 12, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy...

PRNewsWire - 4 months ago

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerati...

PRNewsWire - 4 months ago

NEW YORK, Sept. 30, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presen...

PRNewsWire - 5 months ago

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc.

GlobeNewsWire - 5 months ago

Company plans to further strengthen its regulatory expertise and capabilities as ALS phase 3 clinical trial nears completion in Q4 Company plans to further strengthen its regulatory expertise ...

PRNewsWire - 5 months ago

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

Seeking Alpha - 6 months ago

Brainstorm Cell Therapeutics Inc (BCLI) CEO Chaim Lebovits on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model

PRNewsWire - 7 months ago

NEW YORK, July 8, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opini...

PRNewsWire - 7 months ago

NEW YORK, July 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that f...

PRNewsWire - 8 months ago

NEW YORK, June 24, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new...

GlobeNewsWire - 8 months ago

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced...

PRNewsWire - 8 months ago

NEW YORK, June 11, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim...

PRNewsWire - 8 months ago

WASHINGTON, June 9, 2020 /PRNewswire/ -- The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASD...

PRNewsWire - 8 months ago

NEW YORK, June 3, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ra...

PRNewsWire - 8 months ago

NEW YORK, June 2, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an upd...

PRNewsWire - 8 months ago

NEW YORK, May 27, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that S...

Seeking Alpha - 9 months ago

BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerat...

GlobeNewsWire - 9 months ago

NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, today annou...

GlobeNewsWire - 10 months ago

NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenera...

GlobeNewsWire - 10 months ago

Prof. Frenkel, Chairman of the Group of Thirty (G-30) Board of Trustees, Former Chairman of JPMorgan Chase International and Former Governor of the Bank of Israel Joins the Board to Support th...

GlobeNewsWire - 11 months ago

NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. , ( NASDAQ: BCLI ), a leading developer of cell technologies for neurodegenerative diseases, today announced t...

GlobeNewsWire - 11 months ago

NEW YORK and BOSTON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc . ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debili...

Seeking Alpha - 1 year ago

BrainStorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc ., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announ...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today an...

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that ...

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Lett...

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitat...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurod...

About BCLI

Brainstorm Cell Therapeutics, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is devel... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Chaim Lebovits
Employees
40
Stock Exchange
NASDAQ
Ticker Symbol
BCLI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for BCLI stock is "Hold" and the 12-month stock price forecast is 17.50.

Price Target
$17.50
Analyst Consensus: Hold